Seek Returns

BIO.B vs. CRL: Bio-Rad Laboratories vs. Charles River Laboratories Stock Comparison

How do Bio-Rad Laboratories (BIO.B) and Charles River Laboratories (CRL) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Bio-Rad Laboratories (BIO.B) and Charles River Laboratories (CRL) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.

Company profile comparison for Bio-Rad Laboratories (BIO.B) and Charles River Laboratories (CRL)
Profile ItemBIO.BCRL
NameBio-Rad Laboratories, Inc. Class B Common StockCharles River Laboratories International, Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesLife Sciences Tools & Services
GICS Sub-IndustryLife Sciences Tools & ServicesLife Sciences Tools & Services
Market Capitalization10.49 billion USD16.19 billion USD
CurrencyUSDUSD
ExchangeNYSENYSE
Listing DateSeptember 21, 1999June 23, 2000
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

BIO.B
CRL
GSPC
Loading price history…
Bio-Rad Laboratories (BIO.B) vs. Charles River Laboratories (CRL), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Bio-Rad Laboratories (BIO.B) and Charles River Laboratories (CRL). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Bio-Rad Laboratories (BIO.B) and Charles River Laboratories (CRL). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Bio-Rad Laboratories (BIO.B) and Charles River Laboratories (CRL)
MetricBIO.BCRL
Total Return (1Y)27.69%99.73%
Total Return (3Y, Annualized)9.13%25.73%
Total Return (5Y, Annualized)-12.33%-2.62%

Risk Profile

Drawdown History

BIO.B
CRL
GSPC
Loading price history…
Bio-Rad Laboratories (BIO.B) vs. Charles River Laboratories (CRL), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Bio-Rad Laboratories (BIO.B) and Charles River Laboratories (CRL). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Charles River Laboratories (CRL) trades around 1.05M shares per day on average, while Bio-Rad Laboratories (BIO.B) sees only 11 — a volume gap that can matter for position sizing, exit liquidity, and order execution.

Risk profile metrics for Bio-Rad Laboratories (BIO.B) and Charles River Laboratories (CRL)
MetricBIO.BCRL
Volatility (1Y, Annualized)30.96%47.68%
Beta (5Y)1.001.34
Max Drawdown (5Y)-70.74%-74.73%
Avg. Volume (3M)111.05M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
BIO.B and CRL are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Bio-Rad Laboratories (BIO.B) and Charles River Laboratories (CRL)
MetricBIO.BCRL
Sharpe Ratio (1Y)0.741.99
Sortino Ratio (1Y)1.103.20

Profitability

ROE (TTM)

Bio-Rad Laboratories (BIO.B) at 14.27% sits in the top ROE quartile, while Charles River Laboratories (CRL) at 1.27% is closer to the peer norm — stronger capital efficiency for BIO.B.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.27%

Max
109.18%
BIO.B
14.27%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.27%

Max
109.18%
Q3
6.23%
CRL
1.27%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Charles River Laboratories (CRL): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Bio-Rad Laboratories (BIO.B) at 39.45% converts revenue to bottom-line profit above its industry’s benchmark range, while Charles River Laboratories (CRL) at 1.01% keeps roughly the typical share for its industry.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.45%

BIO.B
39.45%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.01%

Max
18.05%
Q3
4.78%
CRL
1.01%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Charles River Laboratories (CRL): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Bio-Rad Laboratories (BIO.B) at 9.46% and Charles River Laboratories (CRL) at 14.27% run core operations about as efficiently as their industries’ norm — neither stands out on operating profitability.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.46%

Max
83.12%
Q3
14.77%
BIO.B
9.46%
Median
0.00%
Q1
-78.82%
Min
-207.40%

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.27%

Max
83.12%
Q3
14.77%
CRL
14.27%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Charles River Laboratories (CRL): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Bio-Rad Laboratories (BIO.B) and Charles River Laboratories (CRL)
MetricBIO.BCRL
ROE (TTM)14.27%1.27%
ROA (TTM)1.50%4.74%
Net Margin (TTM)39.45%1.01%
Operating Margin (TTM)9.46%14.27%
Gross Margin (TTM)52.19%35.10%

Growth

Revenue Growth

Bio-Rad Laboratories (BIO.B) at 0.65% is around its peer norm for revenue growth, while Charles River Laboratories (CRL) at -0.85% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Charles River Laboratories (CRL): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Charles River Laboratories (CRL) reports EPS growth of -1,555.00%, ranked against its industry; Bio-Rad Laboratories (BIO.B) has no EPS growth figure this period.

Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Charles River Laboratories (CRL): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Bio-Rad Laboratories (BIO.B) and Charles River Laboratories (CRL)
MetricBIO.BCRL
Revenue Growth (YoY)0.65%-0.85%
Revenue Growth (3Y CAGR)-2.68%0.33%
EPS Growth (YoY)---1,555.00%
EPS Growth (3Y CAGR)----

Financial Strength

Current Ratio (MRQ)

Bio-Rad Laboratories (BIO.B) at 3.18 keeps current ratio within its industry’s typical mid-range, while Charles River Laboratories (CRL) at 1.41 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for CRL.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.18

Max
25.13
Q3
12.13
Median
5.52
BIO.B
3.18
Q1
2.47
Min
0.10

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.41

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
CRL
1.41
Min
0.10
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Charles River Laboratories (CRL): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Bio-Rad Laboratories (BIO.B) at 0.18 carries an industry-typical debt-to-equity mix, while Charles River Laboratories (CRL) at 0.87 uses more debt funding than most peers.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.18

Max
1.42
Q3
0.65
BIO.B
0.18
Median
0.15
Q1
0.02
Min
0.00

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.87

Max
1.42
CRL
0.87
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Charles River Laboratories (CRL): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Bio-Rad Laboratories (BIO.B) and Charles River Laboratories (CRL)
MetricBIO.BCRL
Current Ratio (MRQ)3.181.41
Debt / Equity (MRQ)0.180.87
Net Debt / EBITDA-0.732.92

Dividends

Dividend Yield (TTM)

Neither Bio-Rad Laboratories (BIO.B) nor Charles River Laboratories (CRL) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO.B
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

CRL
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Charles River Laboratories (CRL): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Bio-Rad Laboratories (BIO.B) nor Charles River Laboratories (CRL) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO.B
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

CRL
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Charles River Laboratories (CRL): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Bio-Rad Laboratories (BIO.B) and Charles River Laboratories (CRL)
MetricBIO.BCRL
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

Bio-Rad Laboratories (BIO.B) at 10.36 sits in the cheaper P/E ratio quartile, while Charles River Laboratories (CRL) at 367.36 trades above its peer range — a wide earnings-valuation gap relative to industry peers.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.36

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
BIO.B
10.36
Min
0.07

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

367.36

CRL
367.36
Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Charles River Laboratories (CRL): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Bio-Rad Laboratories (BIO.B) at 4.05 and Charles River Laboratories (CRL) at 4.07 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.05

Max
58.18
Q3
25.77
Median
7.30
BIO.B
4.05
Q1
3.01
Min
0.01

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.07

Max
58.18
Q3
25.77
Median
7.30
CRL
4.07
Q1
3.01
Min
0.01
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Charles River Laboratories (CRL): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Bio-Rad Laboratories (BIO.B) at 1.38 sits in the lower P/B ratio quartile against book while Charles River Laboratories (CRL) at 5.01 is valued near its industry’s middle — BIO.B is cheaper on assets, though weigh it against ROE and asset quality.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
BIO.B
1.38
Min
-5.59

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.01

Max
13.53
Q3
6.54
CRL
5.01
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Charles River Laboratories (CRL): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Bio-Rad Laboratories (BIO.B) and Charles River Laboratories (CRL)
MetricBIO.BCRL
P/E Ratio (TTM)10.36367.36
P/S Ratio (TTM)4.054.07
P/B Ratio (MRQ)1.385.01
Free Cash Flow Yield (TTM)2.59%2.74%